Clinical Significance of Substaging and HER2 Expression in Papillary Nonmuscle Invasive Urothelial Cancers of the Urinary Bladder. (scientific article published on 15 July 2015)

Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome.

Q54399364

No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas.

Q54536990

Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.

Q54585164

HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.

Q54587084

Molecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non–Muscle-Invasive Bladder Cancer

Q63966334

Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder

Q82584712

The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables

Q84215941

Comprehensive molecular characterization of urothelial bladder carcinoma

Q28306864

Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients.

Q33751191

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

Q33862786

Expression of pRb, p53, p16 and cyclin D1 and their clinical implications in urothelial carcinoma

Q34159723

Prognostic Significance of Substaging according to the Depth of Lamina Propria Invasion in Primary T1 Transitional Cell Carcinoma of the Bladder

Q34279215

GSTM1 tissue genotype as a recurrence predictor in non-muscle invasive bladder cancer

Q34539958

Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis

Q35407910

HER2 as a target in invasive urothelial carcinoma

Q35755382

Nomograms for prediction of disease recurrence in patients with primary Ta, T1 transitional cell carcinoma of the bladder.

Q36854613

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

Q38119345

A new and highly prognostic system to discern T1 bladder cancer substage.

Q39692438

Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression

Q43527908

Continuous tissue microarray based identification of cancers with homogeneous target expression for successful targeted therapy in clinical routine practice

Q43635123

Measuring the dimension of invasive component in pT1 urothelial carcinoma in transurethral resection specimens can predict time to recurrence

Q44004095

Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization

Q45779319

Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion

Q47198579

Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer.

Q53177490

HER2 status in primary stage T1 urothelial cell carcinoma of the urinary bladder.

Q53200395

P433

issue

P407

language of work or name

English

Q1860

P304